Skin & hair

The Steroid-Free Creams for Delicate Skin

Save

Steroid creams work fast but thin facial skin with repeated use, and the eyelids and mouth area are especially sensitive to that damage. Tacrolimus and pimecrolimus do the same anti-inflammatory job through a different mechanism and carry no thinning risk, which is why dermatologists reach for them on the face even though they cost more and sting more on the first few applications.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why the face needs a different approach

Facial skin, especially around the eyelids and mouth, is thinner than skin on the trunk or limbs, which means it absorbs more of a topical steroid and shows the damage from repeated use sooner: thinning, visible blood vessels, and a rebound rash called perioral dermatitis that flares specifically where steroid cream has been used around the mouth and nose 1. The cream that feeds perioral dermatitis is often the same one reached for reflexively when a facial rash flares, which is part of why dermatologists steer away from steroids on this part of the face specifically. Long-term steroid use on thin facial skin also carries the risk of topical steroid withdrawal, a rebound reaction after stopping that becomes more likely the longer and more potent the steroid exposure has been.

Topical calcineurin inhibitors were developed to fill exactly this gap: an anti-inflammatory strong enough to control eczema without the atrophy risk, and they are part of standard recommended topical therapy for atopic dermatitis, including on skin where a dermatologist would otherwise hesitate to prescribe a steroid for more than a couple of weeks at a time 2. Elsewhere on the body, where a stronger steroid course is often reasonable, matching topical steroid quantity to the area treated — the fingertip unit dosing method dermatologists teach — keeps exposure proportionate; the face simply has a lower threshold before that exposure becomes a problem.

How tacrolimus and pimecrolimus work

Unlike steroids, which broadly suppress immune and skin-cell activity, calcineurin inhibitors block a specific enzyme inside T cells that is required to switch on the inflammatory signals driving eczema. That narrower mechanism is why they do not cause skin thinning: they turn down inflammation locally without suppressing collagen production or thinning the skin's structural layers the way a steroid does with continued use.

Tacrolimus ointment and pimecrolimus cream are the two approved topical calcineurin inhibitors, and both are part of standard skin-directed eczema management in adults and children, used alongside moisturizers and topical steroids during active flares 23. The same drug class also functions as one of the first-line creams for new vitiligo, where clinicians choose between a steroid or tacrolimus cream for vitiligo largely for the same reason: avoiding cumulative steroid exposure on skin that needs months of treatment.

The burning and stinging tradeoff

The most common reason people stop using these creams early is a burning or stinging sensation in the first several days of use, especially on skin that is already cracked or inflamed. It is not an allergic reaction and it is not a sign the medication is wrong for the skin — for most people it fades within a week as the irritated skin barrier settles.

Applying a thin layer, using the cream on calmer days rather than on freshly broken skin, and pre-treating a bad flare with a short course of a mild steroid before switching to the calcineurin inhibitor are common strategies dermatologists use to get someone through this initial period without giving up on it.

Tacrolimus vs pimecrolimus: picking between them

Tacrolimus ointment is generally considered the more potent of the two and is typically reserved for moderate disease, while pimecrolimus cream is milder and often used for milder eczema or more sensitive areas like the eyelids. Both come in strengths appropriate for different ages, and choosing between them is a smaller-scale version of reading the topical steroid strength chart used for steroids: matching strength to how active the disease is and how sensitive the treated skin is.

Ointment formulations in general tend to be more occlusive and moisturizing than creams, which can make tacrolimus feel heavier on the skin but also more effective at retaining moisture during a flare.

The cancer warning label, and what it actually reflects

Both drugs carry an FDA boxed warning about a theoretical cancer risk, added when the drugs were approved based on how the drug class behaves in the body at the much higher, systemic doses used in organ-transplant patients, not on evidence from the topical cream itself. Despite that warning, calcineurin inhibitors remain part of standard dermatology guideline recommendations for eczema, including on the face and in children, because the accumulated clinical experience with the topical form has not changed that guidance 23.

That gap between a label written for a systemic drug and how the topical version is actually used in practice is a reasonable thing to raise directly with a dermatologist, rather than avoiding an effective treatment on the basis of the warning alone.

Where they fit in the larger eczema ladder

Topical calcineurin inhibitors sit alongside topical steroids as first-line topical therapy for eczema, not above or below them on a ladder — many treatment plans use a steroid to bring a flare under control quickly and then switch to a calcineurin inhibitor to maintain that control without the cumulative steroid exposure 2. Moisturizing consistently underneath both reduces the number of flares and lowers how much active medication is needed overall 4.

For eczema that stays moderate-to-severe despite steroids, calcineurin inhibitors, and good moisturizing, the next tier is systemic treatment — oral or injectable medications, including biologics, that work on the immune system more broadly rather than only where cream is applied 5. That escalation is a separate conversation from face-specific care, and usually follows when topical measures are not controlling eczema anywhere on the body, not just the face.

Using them for maintenance, not just flares

Unlike a steroid, which is generally used for a defined burst and then stopped, calcineurin inhibitors are approved for a proactive maintenance approach: applying the cream two or three times a week to areas that flare repeatedly, even when the skin looks clear, to prevent the next flare from starting. This maintenance pattern is part of why they suit the face specifically, where cumulative steroid exposure over months or years is the exact risk being avoided.

Stopping and restarting only when a flare is visible tends to produce a more reactive pattern of treatment; using a calcineurin inhibitor on a set schedule during quiet periods is one of the more evidence-supported ways to reduce how often the skin flares in the first place.

Common questions

Yes, and this is one of their most common uses — eyelid skin is especially thin and steroid creams are generally avoided there for anything beyond brief use. Pimecrolimus is often chosen first for eyelid eczema because it tends to sting less than tacrolimus, though either can be appropriate depending on how active the disease is.

Unlike steroids, these are approved for longer-term use, including a proactive maintenance schedule of a few applications a week on areas that flare repeatedly. There is no fixed cutoff the way there often is with steroids, though a dermatologist typically checks in periodically to confirm the treatment is still the right fit.

Yes, both tacrolimus ointment and pimecrolimus cream are prescription-only in the United States. They are not available over the counter, unlike hydrocortisone, one of the mildest topical steroids sold without one. A dermatologist or primary care clinician typically prescribes a specific strength based on the location being treated and how active the eczema is.

Calcineurin inhibitors trigger a temporary release of a nerve chemical that causes stinging or warmth, especially on skin that is already inflamed or cracked. It is not an allergic reaction, and for most people it fades within the first week of consistent use as the irritated skin barrier settles.

This is a conversation for the prescribing clinician rather than a blanket answer, since the safety picture depends on how much of the body is treated and for how long. Many dermatologists consider limited facial use reasonable when eczema is significant, but the decision is individualized rather than automatic.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When facial eczema needs more than a cream

  • —Facial skin that becomes increasingly red, swollen, or painful rather than improving after starting treatment — this can signal a skin infection or an allergic reaction to the product itself.
  • —New pustules or a spreading rash around the mouth and nose after steroid use, which can indicate perioral dermatitis rather than the original eczema.
  • —Eye pain, blurred vision, or a rash spreading onto the eyelid margin, which warrants prompt evaluation given how close the treatment area is to the eye.
  • —No improvement after several weeks of consistent use, which is worth a follow-up rather than continuing to self-treat indefinitely.

Facial swelling that spreads quickly, eye pain with vision changes, or a rash that spreads rapidly with fever warrants same-day care at urgent care or an emergency room rather than waiting for a routine dermatology appointment.

This article explains how topical calcineurin inhibitors compare with steroid creams for facial eczema. It does not diagnose your skin condition or replace an in-person exam — a dermatologist can confirm the diagnosis and the right treatment for your skin.

References

  1. 1.Searle T, Ali FR, Al-Niaimi F (2021). Perioral dermatitis: Diagnosis, proposed etiologies, and management. Journal of Cosmetic Dermatology. PMID 33751778 ✓Supports that perioral dermatitis is strongly associated with topical corticosteroid use, used here to explain why facial steroid use carries a rebound-rash risk that calcineurin inhibitors avoid.
  2. 2.Sidbury R, Alikhan A, Bercovitch L, et al. (2023). Guidelines of care for the management of atopic dermatitis in adults with topical therapies. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2022.12.029AAD recommendations naming topical calcineurin inhibitors (tacrolimus, pimecrolimus) as standard topical therapy for atopic dermatitis alongside moisturizers and topical corticosteroids, used to support their role in the topical treatment ladder and continued guideline endorsement despite the boxed warning.
  3. 3.Schoch JJ, Anderson KR, Jones AE, Tollefson MM (2025). Atopic Dermatitis: Update on Skin-Directed Management: Clinical Report. Pediatrics. linkAAP clinical report naming topical corticosteroids and calcineurin inhibitors as the anti-inflammatory tier of skin-directed pediatric eczema management, used to support that calcineurin inhibitors are standard in both adults and children and remain guideline-endorsed.
  4. 4.van Zuuren EJ, Fedorowicz Z, Christensen R, et al. (2017). Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews. PMID 28432721 ✓Cochrane review supporting that moisturizers reduce the number of eczema flares and reduce the amount of topical corticosteroid needed when combined with active treatment, used to support that consistent moisturizing lowers overall medication needed.
  5. 5.Sidbury R, Davis DM, Alikhan A, et al. (2024). Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology. PMID 37943240AAD recommendations for phototherapy and systemic therapy, including biologics, in adult atopic dermatitis, used to describe the escalation tier beyond topical treatment for eczema that stays moderate-to-severe.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library